LAUSR

W idespread acknowledgment of the potential for pharmacies to act as pivotal ancillary health care resource sites was real-ized during the COVID-19 pandemic. Unprecedented effort includ- ing swift collaboration and coordination across multiple federal, local, and private sectors was required to provide COVID-19 test- ing and vaccinations to the entire US population. 1 To increase access of those vulnerable and historically most often excluded from access to the nation's health care system (e.g., rural, socioeconomi-cally disadvantaged, racial/ethnic minority), pharmacies across the United States answered the call to action. Pharmacies have shown significant promise in their ability to help tackle other infectious dis- eases, including HIVand sexually transmitted infections (STIs). 2 – 4 Pharmacists can contribute to reduction of HIV risk behaviors among populations who engage in high-risk sex and drug using behaviors, 5 – 8 provide HIV and STI testing, 9 – 13 and enhance HIV and STI treatment and preexposure prophylaxis (PrEP) or postex- posure prophylaxis services. 4,14 – 18 Although the COVID-19 pandemic differs vastly from the HIV pandemic, each disproportion- ately affects poor and racial minority populations. For this reason, we maintain that many of the same pharmacy-based strategies used in the COVID-19 pandemic that have increased accessibility and normalized services are needed for the HIV pandemic. 2,3 In the US Health and Human Services the initiative “ Ending the HIV in the U.S. ” (EHE) with the ambitious goal of reducing new HIV trans-missions to fewer than 1 in 100,000 persons/year by 2030 using 4 evidence-informed strategies: diagnose, treat, prevent, and re- spond. 19 Promising declines in have occurred since